Pharma boards don’t just oversee pipelines—they oversee patent risk. And in 2024, that risk is increasingly measurable, tradable, and—crucially—governable.
Here’s the hook: IP litigation isn’t a legal event. It’s a governance event. The companies that …

Generic drug developers don’t lose to “bad luck.” They lose to unforced errors—especially around formulation patents.
If you’re building a generic portfolio, formulation patents are often where timelines go to die: unexpected claim scope, overlooked de…

Pharma forensics is having a moment—and it’s not just for litigators.
In the last few years, “formulation patents” have quietly become one of the most consequential battlegrounds in drug lifecycle strategy. Not because they’re always the headline-grabb…

Generic developers don’t lose to “bad luck.” They lose to moats.
In pharma, the moat isn’t always the headline patent everyone tracks. It’s often the secondary layer—formulation tweaks, salt selection, polymorphs, particle size, dosing regimens, and …

Patent cliffs aren’t just legal events—they’re supply-chain events.
If you’re building procurement plans, negotiating manufacturing capacity, or forecasting inventory for the next 12–36 months, “patent cliff” is the wrong mental model. The real story…

Most patent searches miss the real fight.
If you’ve ever run an “AI vs. prior art” pilot, you’ve probably focused on the obvious: keywords, synonyms, and the usual suspects. But in chemical and biologic patents, the real prior art often hides in the …

Most pharma teams don’t lose to “bad science.” They lose to bad IP strategy.
If you’re building a next-generation product—or even just trying to extend a franchise—your biggest risk isn’t the molecule. It’s the formulation patent you didn’t plan for….

Formulation Forensics: The Hidden Detective Work Inside Drug Patent Claims
Most people read drug patents like they’re reading a recipe. But the real story is in the forensics—the quiet clues embedded in excipients, process steps, and “seemingly minor” …

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, the rules are familiar: exchange information, identify patents, litigate (or settle), and try …

Generic winners don’t “wait for approval”—they engineer leverage.
In the Paragraph IV world, the 180-day exclusivity clock isn’t just a timeline. It’s a strategic asset. And the companies that consistently “beat brand to market” aren’t necessarily th…